Clinical Trial Update: QUILT-2.025 NANT Neoepitope Yeast Vaccine (YE-NEO-001): Adjuvant Immunotherapy Using a Personalized Neoepitope Yeast-Based Vaccine To Induce T-Cell Responses In Subjects W/ Previously Treated Cancers. [Phase 1]

View source ↗

Summary

Phase 1 trial update for YE-NEO-001, NantBioScience's personalized neoepitope yeast vaccine, evaluating adjuvant immunotherapy to elicit T-cell responses in pre…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Colorectal Cancer
• Head and Neck Squamous Cell Carcinoma
• Hepatocellular Carcinoma
• Melanoma
• Non-small Cell Lung Cancer
• Pancreatic Cancer

Drugs mentioned

• YE-NEO-001 (NANT Neoepitope Yeast Vaccine)

Snippet

Sponsor: NantBioScience, Inc. | Conditions: Colorectal Cancer, Breast Cancer | Phase 1 | Status: ACTIVE_NOT_RECRUITING